The World Health Organization (WHO) is likely to take a decision about Covaxin’s authorization this week after a thorough discussion.
After completing Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age, Hyderabad-based Bharat Biotech submitted the trial data to Drugs and Comptroller General of India (DCGI) which was approved for the use of children below age 18.
The subject Expert Committee on Covid-19 gave its approval for emergency use of Covaxin for children between 2-18 years of age. Since largest Covid-19 vaccination drive is underway, an AIIMS professor suggested the latest trials show that the safety and immunogenicity of Covaxin is almost same on adults and children.
This comes as relief for many parents out there. The World Health Organization (WHO) is likely to take a decision about Covaxin’s authorization this week after a thorough discussion.
The Brief. Sign up to receive the top stories you need to know right now.